7.97 0.00 (0.00%)
After hours: 4:19PM EST
Previous Close | 7.89 |
Open | 7.92 |
Bid | 7.71 x 1000 |
Ask | 8.98 x 800 |
Day's Range | 7.68 - 8.08 |
52 Week Range | 5.49 - 18.94 |
Volume | 148,625 |
Avg. Volume | 290,701 |
Market Cap | 332.151M |
Beta (3Y Monthly) | 0.24 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.31 |
Earnings Date | Feb 25, 2020 - Mar 2, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28.68 |
Shares of ProQR Therapeutics rose 10% in premarket trading after it said the Food and Drug Administration had granted an orphan-drug designation to QR-1123. The experimental therapy is being tested as a treatment for vision loss caused by autosomal dominant retinitis pigmentosa (adrp), a rare eye disease. "Our goal is to develop and actively advance a pipeline of programs that can treat inherited retinal diseases like adRP in a targeted manner," ProQR CEO Daniel de Boer said in a news release. ProQR stock is down 51% year-to-date, while the S&P 500 has gone up 24%.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. ODD provides a special status for investigational drugs being developed for rare diseases.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 18, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Blueprint Medicines' (BPMC) loss is narrower than estimated in the third quarter with revenues also beating the mark. Shares rise.
ProQR (PRQR) delivered earnings and revenue surprises of -9.38% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1.
Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.
BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.
As of late, it has definitely been a great time to be an investor ProQR Therapeutics.
Citigroup Global Markets and Evercore ISI acted as joint bookrunners for the offering. Cantor Fitzgerald & Co. and JMP Securities acted as lead managers, with Chardan and Kempen acting as co-managers.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals ...
LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the pricing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share. All of the shares are being offered by ProQR. In addition, ProQR has granted the underwriters a 30-day option to purchase up to 1,363,636 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
ProQR Therapeutics N.V. (PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it intends to offer and sell $50,000,000 of its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $7,500,000 of ordinary shares, on the same terms and conditions.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...
ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced positive top-line results from the PQ-110-001 study, a Phase 1/2 dose range finding, first-in-human trial of sepofarsen (QR-110) in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. “We reported today that patients receiving sepofarsen had a clinically meaningful improvement in vision, and in some cases the patient’s vision improved to a level that could be deemed life changing. This is very encouraging for the LCA10 community and the Inherited Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual Sciences and Principal Investigator at the University of Iowa.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that management will present and discuss top-line results from the Phase 1/2 study of sepofarsen on October 10, ahead of the American Academy of Ophthalmology's annual meeting to be held in San Francisco, CA, U.S. PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Two dose levels are being tested, 80 μg (160 μg loading dose) and 160 μg (320 μg loading dose).
ProQR Therapeutics N.V. (PRQR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 30, 2019 -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track designation from the Food and Drug Administration (FDA) for QR-1123. QR-1123 is a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H mutation in the rhodopsin (RHO) gene. Fast Track designation is granted by the FDA to drugs in development for serious conditions with the potential to fulfill an unmet medical need.
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.